Athenex (Athenex) Scaled Net Operating Assets : -0.06 (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Athenex's operating assets for the quarter that ended in Dec. 2022 was $172.5 Mil. Athenex's operating liabilities for the quarter that ended in Dec. 2022 was $185.9 Mil. Athenex's Total Assets for the quarter that ended in Sep. 2022 was $228.4 Mil. Therefore, Athenex's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2022 was -0.06.

Athenex Scaled Net Operating Assets Historical Data

The historical data trend for Athenex's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Scaled Net Operating Assets Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.49

0.34

0.37

0.36

-0.05

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.36	0.44	0.10	0.06	-0.06

Competitive Comparison of Athenex's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Athenex's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Athenex's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Athenex's Scaled Net Operating Assets falls into.

Athenex Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Athenex's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(172.547	-	185.878)	/	267.448
=	-0.05

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	204.055	-	31.508
=	172.547

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	228.236	-	3.144	-	39.214
=	185.878

Athenex's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2022 )
=	(Operating Assets (Q: Dec. 2022 )	-	Operating Liabilities (Q: Dec. 2022 ))	/	Total Assets (Q: Sep. 2022 )
=	(172.547	-	185.878)	/	228.35
=	-0.06

where

	Operating Assets		(Q: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	204.055	-	31.508
=	172.547

	Operating Liabilities		(Q: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	228.236	-	3.144	-	39.214
=	185.878

Athenex Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Athenex's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (Athenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Executives

Jinn Wu	director	107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam	director, officer: CEO and Chairman of the Board
Joe Annoni	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook	officer: See Remarks	C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang	officer: Pres Cell Therapy, VP Corp Dev	C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan	director, officer: EVP, Chief Medical Officer	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski	officer: Chief Scientific Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams	officer: Interim Chief Acct Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell	director	3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo	officer: President, China	3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok	director	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203